|
1
|
Gomes MA, Priolli DG, Tralhão JG and
Botelho MF: Hepatocellular carcinoma: Epidemiology, biology,
diagnosis, and therapies. Rev Assoc Med Bras. 1992.59:514–524.
2013. View Article : Google Scholar
|
|
2
|
Herszényi L and Tulassay Z: Epidemiology
of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci.
14:249–258. 2010.PubMed/NCBI
|
|
3
|
Ribatti D, Vacca A, Nico B, Sansonno D and
Dammacco F: Angiogenesis and anti-angiogenesis in hepatocellular
carcinoma. Cancer Treat Rev. 32:437–444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pang RW and Poon RT: From molecular
biology to targeted therapies for hepatocellular carcinoma: The
future is now. Oncology. 72 Suppl 1:S30–S44. 2007. View Article : Google Scholar
|
|
5
|
Castroagudín JF, Delgado M, Villanueva A,
Bustamante M, Martínez J, Otero E, Tomé S, Martínez SM, Segade FR,
Conde R, et al: Safety of percutaneous ethanol injection as
neoadjuvant therapy for hepatocellular carcinoma in waiting list
liver transplant candidates. Transplant Proc. 37:3871–3873. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gluer AM, Cocco N, Laurence JM, Johnston
ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic
review of actual 10-year survival following resection for
hepatocellular carcinoma. HPB (Oxford). 14:285–290. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou XD: Recurrence and metastasis of
hepatocellular carcinoma: Progress and prospects. Hepatobiliary
Pancreat Dis Int. 1:35–41. 2002.PubMed/NCBI
|
|
8
|
Altenburg JD, Harvey KA, McCray S, Xu Z
and Siddiqui RA: A novel 2,6-diisopropylphenyl-docosahexaenoamide
conjugate induces apoptosis in T cell acute lymphoblastic leukemia
cell lines. Biochem Biophys Res Commun. 411:427–432. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mammoto T, Mukai M, Mammoto A, Yamanaka Y,
Hayashi Y, Mashimo T, Kishi Y and Nakamura H: Intravenous
anesthetic, propofol inhibits invasion of cancer cells. Cancer
Lett. 184:165–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miao Y, Zhang Y, Wan H, Chen L and Wang F:
GABA-receptor agonist, propofol inhibits invasion of colon
carcinoma cells. Biomed Pharmacother. 64:583–588. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang ZT, Gong HY, Zheng F, Liu DJ and Dong
TL: Propofol suppresses proliferation and invasion of pancreatic
cancer cells by upregulating microRNA-133a expression. Genet Mol
Res. 14:7529–7537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang ZT, Gong HY, Zheng F, Liu DJ and Yue
XQ: Propofol suppresses proliferation and invasion of gastric
cancer cells via downregulation of microRNA-221 expression. Genet
Mol Res. 14:8117–8124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Zhang D, Wu GQ, Feng ZY and Zhu
SM: Propofol inhibits the adhesion of hepatocellular carcinoma
cells by upregulating microRNA-199a and downregulating MMP-9
expression. Hepatobiliary Pancreat Dis Int. 12:305–309. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Wu GQ, Zhang Y, Feng ZY and Zhu
SM: Propofol induces apoptosis of hepatocellular carcinoma cells by
upregulation of microRNA-199a expression. Cell Biol Int.
37:227–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Shan WF, Jin TT, Wu GQ, Xiong XX,
Jin HY and Zhu SM: Propofol exerts anti-hepatocellular carcinoma by
microvesicle-mediated transfer of miR-142-3p from macrophage to
cancer cells. J Transl Med. 12:2792014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morishita A, Zaidi MR, Mitoro A,
Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K:
HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee CT, Zhang L, Mounajjed T and Wu TT:
High mobility group AT-hook 2 is overexpressed in hepatoblastoma.
Hum Pathol. 44:802–810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marijon H, Dokmak S, Paradis V, Zappa M,
Bieche I, Bouattour M, Raymond E and Faivre S:
Epithelial-to-mesenchymal transition and acquired resistance to
sunitinib in a patient with hepatocellular carcinoma. J Hepatol.
54:1073–1078. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan EJ, Thuault S, Caja L, Carletti T,
Heldin CH and Moustakas A: Regulation of transcription factor Twist
expression by the DNA architectural protein high mobility group A2
during epithelial-to-mesenchymal transition. J Biol Chem.
287:7134–7145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thuault S, Tan EJ, Peinado H, Cano A,
Heldin CH and Moustakas A: HMGA2 and Smads co-regulate SNAIL1
expression during induction of epithelial-to-mesenchymal
transition. J Biol Chem. 283:33437–33446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zha L, Zhang J, Tang W, Zhang N, He M, Guo
Y and Wang Z: HMGA2 elicits EMT by activating the Wnt/β-catenin
pathway in gastric cancer. Dig Dis Sci. 58:724–733. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsuchiya M, Asada A, Arita K, Utsumi T,
Yoshida T, Sato EF, Utsumi K and Inoue M: Induction and mechanism
of apoptotic cell death by propofol in HL-60 cells. Acta
Anaesthesiol Scand. 46:1068–1074. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Inada T, Kubo K and Shingu K: Possible
link between cyclooxygenase-inhibiting and antitumor properties of
propofol. J Anesth. 25:569–575. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su Z, Hou XK and Wen QP: Propofol induces
apoptosis of epithelial ovarian cancer cells by upregulation of
microRNA let-7i expression. Eur J Gynaecol Oncol. 35:688–691.
2014.PubMed/NCBI
|
|
25
|
Ye Z, Jingzhong L, Yangbo L, Lei C and
Jiandong Y: Propofol inhibits proliferation and invasion of
osteosarcoma cells by regulation of microRNA-143 expression. Oncol
Res. 21:201–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou X, Benson KF, Ashar HR and Chada K:
Mutation responsible for the mouse pygmy phenotype in the
developmentally regulated factor HMGI-C. Nature. 376:771–774. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Langelotz C, Schmid P, Jakob C, Heider U,
Wernecke KD, Possinger K and Sezer O: Expression of
high-mobility-group-protein HMGI-C mRNA in the peripheral blood is
an independent poor prognostic indicator for survival in metastatic
breast cancer. Br J Cancer. 88:1406–1410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Liu X, Li AY, Chen L, Lai L, Lin
HH, Hu S, Yao L, Peng J, Loera S, et al: Overexpression of HMGA2
promotes metastasis and impacts survival of colorectal cancers.
Clin Cancer Res. 17:2570–2580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sarhadi VK, Wikman H, Salmenkivi K, Kuosma
E, Sioris T, Salo J, Karjalainen A, Knuutila S and Anttila S:
Increased expression of high mobility group A proteins in lung
cancer. J Pathol. 209:206–212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu L, Wang Z, Lu R and Jiang W: Expression
of high mobility group A2 is associated with poor survival in
hepatocellular carcinoma. Pathol Oncol Res. 18:983–987. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gupta A, Verma A, Mishra AK, Wadhwa G,
Sharma SK and Jain CK: The Wnt pathway: Emerging anticancer
strategies. Recent Pat Endocr Metab Immune Drug Discov. 7:138–147.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rosenbluh J, Wang X and Hahn WC: Genomic
insights into WNT/β-catenin signaling. Trends Pharmacol Sci.
35:103–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai C, Stolz DB, Kiss LP, Monga SP,
Holzman LB and Liu Y: Wnt/beta-catenin signaling promotes podocyte
dysfunction and albuminuria. J Am Soc Nephrol. 20:1997–2008. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Breuhahn K, Longerich T and Schirmacher P:
Dysregulation of growth factor signaling in human hepatocellular
carcinoma. Oncogene. 25:3787–3800. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baulida J and García de Herreros A:
Snail1-driven plasticity of epithelial and mesenchymal cells
sustains cancer malignancy. Biochim Biophys Acta. 1856:55–61.
2015.PubMed/NCBI
|
|
36
|
Vita M and Henriksson M: The Myc
oncoprotein as a therapeutic target for human cancer. Semin Cancer
Biol. 16:318–330. 2006. View Article : Google Scholar : PubMed/NCBI
|
